Aimmune Therapeutics Inc (AIMT) short interest is $167 million; 6.90 million shares shorted; 18.09% of float; stock borrow cost is 30 bps fee (general collateral).
AIMT shares shorted have been relatively stable in 2019, up only 259k, +3.90% in 2019. But we saw an steady increase in February, with 356k shares shorted, a 5.44% increase.
We are seeing increased shorting ahead of earnings today, and with 97k shares shorted over the last week there is strong negative trading sentiment in the security.
Want deeper insight into the above analysis?
Contact:Ā [email protected]
Managing Director Predictive Analytics, S3 Partners, LLC
For more information on S3ās reporting, data and analytics solutions, email us at [email protected]. Start your free trial of the BLACK App ā the only source of real-time short interest on the Bloomberg Terminal or Thomson Reuters Eikon.
For short side data and access to our research reports go to https://shortsight.com/.
The information herein (some of which has been obtained from third party sources without verification) is believed by S3 Partners, LLC (āS3 Partnersā) to be reliable and accurate.Ā Neither S3 Partners nor any of its affiliates makes any representation as to the accuracy or completeness of the information herein or accepts liability arising from its use.Ā Prior to making any decisions based on the information herein, you should determine, without reliance upon S3 Partners, the economic risks and merits, as well as the legal, tax, accounting and investment consequences, of such decisions.